Treatment of the first episode of schizophrenia: An update on pharmacologic and psychological interventions

Current Psychiatry Reports

Volumn 10, Issue 3, 2008, Pages 202-209

  Crespo Facorro, Benedicto ^a   Pérez Iglesias, Rocío ^b   González Blanch, Cesar ^b   Mata, Ignacio ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SULPIRIDE;

AKATHISIA; ANTICHOLINERGIC SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMMUNICATION SKILL; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; FAMILY THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; KETOACIDOSIS; LOW DRUG DOSE; METABOLIC DISORDER; PARKINSONISM; PHARMACOGENETICS; PROBLEM SOLVING; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL SUPPORT; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; HUMANS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 49249091591     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0034-1     Document Type: Review

References (50)

1. Emsley RA: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999, 25:721-729.
2. Lieberman JA, Tollefson G, Tohen M, et al.: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003, 160:1396-1404.
3. Schooler N, Rabinowitz J, Davidson M, et al.: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005, 162:947-953.
4. Green AI, Lieberman JA, Hamer RM, et al.: Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006, 86:234-243.
5. McEvoy JP, Lieberman JA, Perkins DO, et al.: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1050-1060.
6. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al.: A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006, 67:1511-1521.
7. Leucht S, Pitschel-Walz G, Abraham D, et al.: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999, 35:51-68.
8. Robinson DG, Woerner MG, Napolitano B, et al.: Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006, 163:2096-2102.
9. Sanger TM, Lieberman JA, Tohen M, et al.: Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999, 156:79-87.
10. Lieberman JA, Phillips M, Gu H, et al.: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28:995-1003.
11. Keefe RS, Seidman LJ, Christensen BK, et al.: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004, 161:985-995.
12. Keefe RS, Seidman LJ, Christensen BK, et al.: Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006, 59:97-105.
13. Harvey PD, Rabinowitz J, Eerdekens M, et al.: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005, 162:1888-1895.
14. Purdon SE, Jones BD, Stip E, et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000, 57:249-258.
15. Goldberg TE, Goldman RS, Burdick KE, et al.: Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007, 64:1115-1122.
16. Keefe RS, Sweeney JA, Gu H, et al.: Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1061-1071.
17. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al.: Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 2008, 99:13-22.
18. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al.: A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007, 68:1733-1740.
19. Zipursky RB, Gu H, Green AI, et al.: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005, 187:537-543.
20. Bushe CJ, Leonard BE: Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007, 68:1682-1690.
21. Wu RR, Zhao JP, Liu ZN, et al.: Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006, 186:572-578.
22. Graham KA, Perkins DO, Edwards LJ, et al.: Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005, 162:118-123.
23. Sengupta SM, Klink R, Stip E, et al.: Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res 2005, 80:131-133.
24. Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64:701-723.
25. Kopala LC, Good KP, Milliken H, et al.: Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res 2006, 81:29-39.
26. Leysen J: Receptor profile of antipsychotics. In Atypical Antipsychotics. Edited by Ellenbroek BA, Cools AR. Basel, Switzerland: Bikhduser Verlag; 2000:57-81.
27. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007, 12:707-747.
28. Aquilante CL, Lobmeyer MT, Langaee TY, et al.: Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004, 24:720-726.
29. James HM, Coller JK, Gillis D, et al.: A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 2004, 42:719-723.
30. Skarke C, Kirchhof A, Geisslinger G, et al.: Rapid genotyping for relevant CYP1A2 alletes by pyrosequencing. Eur J Clin Pharmacol 2005, 61:887-892.
31. Arranz MJ, Munro J, Birkett J, et al.: Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
32. Bakker PR, van Harten PN, van Os J: Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006, 83:185-192.
33. Reynolds GP, Zhang ZJ, Zhang XB: Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359:2086-2097.
34. Templeman LA, Reynolds GP, Arranz B, et al.: Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200.
35. Pilling S, Bebbington P, Kuipers E, et al.: Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002, 32:763-782.
36. Gutierrez-Recacha P, Chisholm D, Hato JM, et al.: Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatr Scand Suppl 2006, 432:29-38.
37. Mojtabai R, Nicholson RA, Carpenter BN: Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull 1998, 24:569-587.
38. de Haan L, Linszen DH, Lenior ME, et al.: Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull 2003, 29:341-348.
39. Penn DL, Waldheter EJ, Perkins DO, et al.: Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005, 162:2220-2232.
40. Lewis S, Tarrier N, Haddock G, et al.: Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry Suppl 2002, 43:01-07.
41. Tarrier N, Lewis S, Haddock G, et al.: Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry 2004, 184:231-239.
42. Jackson H, McGorry P, Edwards J, et al.: A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. Psychol Med 2005, 35:1295-1306.
43. Jackson HJ, McGorry PD, Killackey E, et al.: Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. Psychol Med 2007 Nov 16 (Epub ahead of print).
44. Edwards J, Elkins K, Hinton M, et al.: Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006, 114:109-117.
45. Power PJ, Bell RJ, Mills R, et al.: Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust N Z J Psychiatry 2003, 37:414-420.
46. Gumley A, O'Grady M, McNay L, et al.: Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychol Med 2003, 33:419-431.
47. Zhang M, Wang M, Li J, Phillips MR: Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 1994, Aug:96-102.
48. Lenior ME, Dingemans PM, Linszen DH, et al.: Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. Br J Psychiatry 2001, 179:53-58.
49. Askey R, Gamble C, Gray R: Family work in first-onset psychosis: a literature review. J Psychiatr Ment Health Nurs 2007, 14:356-365.
50. Lewis SW, Tarrier N, Drake RJ: Integrating non-drug treatments in early schizophrenia. Br J Psychiatry Suppl 2005, 48:s65-s71.